News & Events

Keep upto date with all the latest news and insights from Nanopharm.

  • Nanopharm Ltd acquired by AptarGroup

    Read the full press release

    Read More
  • Join us at InspireMe in San Francisco, June 4-5, 2019.

    InspireMe promises to be the DPI and Soft Mist industry event of the year.

    Read More
  • Meet disruptive innovation at RDD Europe 2019

    Nanopharm is creating value for our clients through disruptive innovation in respiratory product development.

    Read More
  • Nanopharm Limited & Sciarra Laboratories Inc

    Announce Strategic Alliance

    Read More
  • Nanopharm Announce Appointment of Head of Device Development

    Device Development Established at Nanopharm Ltd

    Read More
  • Nanopharm Announces Appointment of Chairman

    Nanopharm Announces the Appointment of Mark Clement as Chairman of the Board

    Read More
  • Addition of the Malvern G3-ID at Nanopharm

    Demonstrating bioequivalence (BE) for complex generics such as nasal spray suspension drug products is a challenging task. Sponsors not only have to consider device requirements but also understand the properties of the API in the presence of functional excipients.

    Read More
  • New research into in vitro strategies for demonstrating bioequivalence in generic nasal sprays

    Nanopharm Ltd, supported by Malvern instruments and with funding from the Food and Drug Administration (FDA), have carried out experimental studies to identify analytical strategies that can help bring generic nasal sprays to market faster.

    Read More